We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Gilead Signs Licensing Agreements with Generic Drugmakers for COVID-19 Therapy Remdesivir

By HospiMedica International staff writers
Posted on 14 May 2020
Gilead Sciences (Foster City, CA, USA) has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers to further expand the supply of remdesivir.

The agreements allow the companies – Cipla Ltd., Ferozsons Laboratories Ltd., Hetero Labs Ltd., Jubilant Lifesciences, and Mylan – based in India and Pakistan to manufacture remdesivir for distribution in 127 countries. More...
The countries consist of nearly all low-income and lower-middle income countries, as well as several upper-middle- and high-income countries that face significant obstacles to healthcare access.

Under the licensing agreements, the companies have a right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly. The licensees also set their own prices for the generic product they produce. The licenses are royalty-free until the World Health Organization declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat or prevent COVID-19, whichever is earlier.

Related Links:
Gilead Sciences


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Tourniquet System
heidi– mein Tourniquet
New
Fetal Monitor
BT-380
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
image: Principles of SMEAR-ULM. (Lai, Y., Argüello, A.N., Liu, M. et al., Nature Sensors (2026). DOI: 10.1038/s44460-026-00078-4)

“Intelligent Tattoo” Method Detects Early Melanoma Signals

Melanoma is a lethal skin cancer in which earlier detection drives better outcomes. Current evaluation relies on visual inspection followed by biopsy, which can miss nascent lesions and lead to unnecessary... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.